ArticleScience advances2022
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
23.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- The Role of Cannabidiol in Liver Disease: A Systemic Review.International journal of molecular sciences · 2024Pooled it
- Article
- Co-exposure to cannabinoids and nicotine increases senescence in prenatal human lung development.Pediatric research · 2026Article
- Article
- Selected Cannabinoids, Cannabimimetic Agents andPharmaceuticals (Basel, Switzerland) · 2026Review
- Cannabidiol for Mucosal Diseases: Therapeutic Potential and Advanced Delivery Strategies.Pharmaceutics · 2026Review
- Inhibitory effect of cannabidiol on infectious bronchitis virus in chickens in vitro and in vivo.Archives of microbiology · 2026Article
- Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBPJournal for immunotherapy of cancer · 2026Article
- Viral Vertical Transmission through the Placenta: The Potential of Natural Products as Therapeutic and Prophylactic Antiviral Agents.Current topics in medicinal chemistry · 2026Review
- Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV-2 Antiviral Activities and Lack of Translatability.Journal of medicinal chemistry · 2025Review
- Novel Multifunctional Cannabidiol-Based Analogues with In Silico, In Vitro, and In Vivo Anti-SARS-CoV-2 Effect.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Cannabis Derivatives as Ingredients of Functional Foods to Combat the COVID-19 Pandemic.Foods (Basel, Switzerland) · 2025Review
- Anti-Infective Screening of Selected Nine Cannabinoids AgainstCurrent issues in molecular biology · 2025Article
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors.Nature chemical biology · 2025Article
- Secondary metabolite profiles and anti-SARS-CoV-2 activity of ethanolic extracts from nine genotypes of Cannabis sativa L.Archiv der Pharmazie · 2025Article
- Cannabidiol polarizes human neutrophils toward a cancer-promoting phenotype.Frontiers in immunology · 2025Article
- Transcriptomic Analysis of HPV-Positive Oesophageal Tissue Reveals Upregulation of Genes Linked to Cell Cycle and DNA Replication.International journal of molecular sciences · 2024Article
- Establishment of a human organoid-based evaluation system for assessing interspecies infection risk of animal-borne coronaviruses.Emerging microbes & infections · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
33 authors at 4 institutions in 1 country.
Long Chi NguyenBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-4637-2331
Dongbo YangBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-8343-5477
Vlad NicolaescuDepartment of Microbiology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-6347-0232
Thomas J BestCenter for Health and the Social Sciences, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0654-6250
Haley GulaDepartment of Microbiology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-8475-7435
Divyasha SaxenaCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.
Jon D GabbardCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.
Shao-Nong ChenPharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0003-0748-0863
Takashi OhtsukiPharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
John Brent FriesenPharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-0739-9224
Nir DraymanPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-4460-9558
Adil MohamedPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Christopher DannBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.
Diane SilvaDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.
Lydia Robinson-MailmanBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.
Andrea ValdespinoBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.
Letícia StockBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-6302-1373
Eva SuárezBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.
Krysten A JonesDepartment of Chemistry, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0711-5516
Saara-Anne AziziDepartment of Chemistry, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-9226-9917
Jennifer K DemarcoCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.ORCID 0000-0003-4807-6250
William E SeversonCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.
Charles D AndersonCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.
James Michael MillisDepartment of Surgery, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-5361-5776
Bryan C DickinsonDepartment of Chemistry, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-9616-1911
Savaş TayPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-1912-6020
Scott A OakesDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-2099-2249
Guido F PauliPharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0003-1022-4326
Kenneth E PalmerCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40222, USA.ORCID 0000-0002-2811-1111
National COVID Cohort Collaborative ConsortiumORCID 0000-0001-5437-2545
David O MeltzerCenter for Health and the Social Sciences, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-2790-7393
Glenn RandallDepartment of Microbiology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-7417-3615
Marsha Rich RosnerBen May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-6586-8335
University of Chicago · USUniversity of Louisville · USUniversity of Illinois Chicago · USArgonne National Laboratory · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MClinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1MProject-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MPhenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4MTransform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MThe Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0MImplementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MGates Foundation INV-018455NCATS NIH HHS U24 TR002306NCATS NIH HHS UL1 TR001412NCATS NIH HHS UL1 TR001414NCATS NIH HHS UL1 TR001420NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001425NCATS NIH HHS UL1 TR001430NCATS NIH HHS UL1 TR001433NCATS NIH HHS UL1 TR001436NCATS NIH HHS UL1 TR001439NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR001445NCATS NIH HHS UL1 TR001449NCATS NIH HHS UL1 TR001450NCATS NIH HHS UL1 TR001453NCATS NIH HHS UL1 TR001855NCATS NIH HHS UL1 TR001860NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR001866NCATS NIH HHS UL1 TR001872NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR001876NCATS NIH HHS UL1 TR001878NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR001998NCATS NIH HHS UL1 TR002001NCATS NIH HHS UL1 TR002003NCATS NIH HHS UL1 TR002014NCATS NIH HHS UL1 TR002240NCATS NIH HHS UL1 TR002243NCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002366NCATS NIH HHS UL1 TR002369NCATS NIH HHS UL1 TR002373NCATS NIH HHS UL1 TR002377NCATS NIH HHS UL1 TR002378NCATS NIH HHS UL1 TR002384NCATS NIH HHS UL1 TR002389NCATS NIH HHS UL1 TR002489NCATS NIH HHS UL1 TR002494NCATS NIH HHS UL1 TR002529NCATS NIH HHS UL1 TR002535NCATS NIH HHS UL1 TR002537NCATS NIH HHS UL1 TR002538NCATS NIH HHS UL1 TR002541NCATS NIH HHS UL1 TR002544NCATS NIH HHS UL1 TR002550NCATS NIH HHS UL1 TR002553NCATS NIH HHS UL1 TR002556NCATS NIH HHS UL1 TR002645NCATS NIH HHS UL1 TR002649NCATS NIH HHS UL1 TR002733NCATS NIH HHS UL1 TR002736NCATS NIH HHS UL1 TR003015NCATS NIH HHS UL1 TR003017NCATS NIH HHS UL1 TR003096NCATS NIH HHS UL1 TR003098NCATS NIH HHS UL1 TR003107NCATS NIH HHS UL1 TR003142NCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA184494NCI NIH HHS R01 CA219815NIAID NIH HHS R01 AI127518NIAID NIH HHS R01 AI134980NIAID NIH HHS R01 AI137514NIGMS NIH HHS R01 GM121735NIGMS NIH HHS R35 GM119840NIGMS NIH HHS U54 GM104938NIGMS NIH HHS U54 GM104940NIGMS NIH HHS U54 GM104941NIGMS NIH HHS U54 GM104942NIGMS NIH HHS U54 GM115428NIGMS NIH HHS U54 GM115458NIGMS NIH HHS U54 GM115516NIGMS NIH HHS U54 GM115677
Abstract
The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.
Indexed as
A549 CellsAnimalsAntiviral AgentsCannabidiolChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentEndoplasmic Reticulum StressEndoribonucleasesEpithelial CellsFemaleGene Expression Regulation, ViralHost-Pathogen InteractionsHumansImmunity, InnateInterferonsAntiviral AgentsCannabidiolEndoribonucleasesERN1 protein, humanInterferonsProtein Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.